Schrödinger's AI co-scientist Bunsen drives record ACV growth and BMS deal
Bunsen AI co-scientist launch Schrödinger launched Bunsen, an AI co-scientist that combines physics-based simulation with AI to speed up molecular discovery. This new product opens a fresh revenue stream and makes its platform stickier, pushing the stock up as investors bet on future sales.
Bunsen is the core new product driving both the BMS deal and the Q2 ACV surge.
Bristol Myers Squibb adopts Bunsen at scale Bristol Myers Squibb signed a strategic deal to deploy Bunsen across its research teams. A major pharma customer expanding use validates the technology and adds recurring software revenue, lifting the stock as it shows real commercial traction.
The BMS deal is a concrete new customer win that directly boosts revenue potential.
Q2 ACV jumps 27%, guidance raised Schrödinger reported 27% year-over-year growth in annual contract value to $29.6 million, turned a net profit, and raised drug discovery revenue guidance. Strong demand and better profitability signal the business is accelerating, pushing the stock higher.
Q2 results show the strongest growth yet and a swing to profit, key for investor confidence.
AI drug discovery investment boom Industry reports show AI drug discovery investment topped $2 billion and cuts timelines by 70%. Schrödinger is named a key player, so rising sector interest draws more attention and potential customers to its platform, supporting the stock price.
The sector tailwind amplifies Schrödinger's growth story and attracts investor interest.